Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035100
Status:
COMPLETED
Last Update Posted:
2012-04-16
First Post:
2002-05-02
Brief Title:
EPO906 Therapy in Patients With Advanced Ovarian Primary Fallopian or Primary Peritoneal Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Ovarian Primary Fallopian or Primary Peritoneal Cancer
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine whether the new investigational drug EPO906 given by intravenous infusion IV directly into the vein is effective in shrinking tumors and preventing the growth of cells that cause ovarian fallopian or peritoneal cancers Recruitment in the United States is complete but the study is still enrolling in other countries
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None